Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Total Liabilities
Everything the company owes to creditors and other parties.
Sionna Therapeutics, Inc.NASDAQ: SION
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 6.0% from a year ago
Total liabilities stood at $16.83M at the end of Q1 FY2026, down 6.0% from a year earlier and down 12.0% from the prior quarter. Over 3 fiscal years it compounded at -50.5% a year.
Context
- Total liabilities amounted to 5.5% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -6.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 19.12M USD
- Year-over-year change
- -94.5%
- 3-year CAGR
- -50.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.12M | -94.5% |
| FY2024 | 2024-12-31 | 349.47M | +109.5% |
| FY2023 | 2023-12-31 | 166.83M | +6.1% |
| FY2022 | 2022-12-31 | 157.29M | — |
Total Liabilities vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 total liabilities of $16.83M is the lowest of the 11 companies compared; the peer median is $240.56M.
- Its year-over-year change of -6.0% is the 10th highest of 11, against a peer median of +39.2%.
- Total liabilities amounts to 5.5% of total assets for SION, versus a peer median of 26.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $918.16M | +1089.2% | -20.6% | 78.0% | |
| Sep 2026 | $437.36M | +11.6% | +8.2% | 29.2% | |
| Mar 2026 | $379M | +8.1% | +7.3% | 96.7% | |
| Jun 2026 | $358.52M | -13.8% | +48.1% | 96.7% | |
| Mar 2026 | $355.89M | +34.5% | +53.9% | 70.5% | |
| Jun 2026 | $125.23M | +13.6% | +33.7% | 23.5% | |
| Mar 2026 | $86.69M | +126.3% | +5.4% | 8.4% | |
| Mar 2026 | $78.01M | +91.3% | -4.6% | 18.6% | |
| Sep 2026 | $72.06M | +43.9% | +28.1% | 10.0% | |
| Sep 2026 | $51.22M | +44.5% | +87.6% | 10.1% | |
| Mar 2026 | $16.83M | -6.0% | -50.5% | 5.5% | |
| Peer median (excluding SION) | $240.56M | +39.2% | +18.2% | 26.3% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.